SHOX2_PTGER4 DNA Methlyation in Lung Cancer (Epi1)

University Hospital Essen

Status: Completed

Conditions: Lungcancer

Treatments: Genetic: lung cancer

Study type: Observational

Funder types: Other

Identifiers

NCT04321499

SHOX2 and PTGER4

Details and patient eligibility

About

Data on SHOX2 and PTGER4 DNA Methylation suggest possible use as a biomarker for early lung cancer diagnosis.

In this study a control group consisting of COPD patients with a CT-scan of the chest no older than 6 weeks and a control group of patients with a nodule and ruled out diagnosis of lung cancer will be included.

SHOX2 and PTGER4 will be analyzed via PCR.

Full description

Data on SHOX2 and PTGER4 DNA Methylation suggest possible use as a biomarker for early lung cancer diagnosis.

In this study a control group consisting of COPD patients with a CT-scan of the chest no older than 6 weeks and a control group of patients with a nodule and ruled out diagnosis of lung cancer will be included.

A total of 150 patients will be enrolled in this study. SHOX2 and PTGER4 will be analyzed via PCR of blood plasma samples.

Enrollment: 70 patients

Sex: All

Ages: 18 to 95 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

suspicious finding for lung cancer on CT-scan

Exclusion criteria

• history significant for former malignant diseases

Trial design

70 participants in 2 patient groups

lung cancer

Description:

stage IA-IIIA lung cancer

Treatment:

Genetic: lung cancer

benign nodules

Description:

ruled out lung cancer via Operation or CT-scan follow-up

Treatment:

Genetic: lung cancer